Advertisement

Topics

Eisai, UCL Alliance Advances Alzheimer\'s Candidate

03:43 EST 7 Dec 2018 | Contract Pharma

Phase I trial of E2814, an anti-tau monoclonal antibody, will assess the ability to slow the progression of AD

Original Article: Eisai, UCL Alliance Advances Alzheimer\'s Candidate

NEXT ARTICLE

More From BioPortfolio on "Eisai, UCL Alliance Advances Alzheimer\'s Candidate"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...

Antibodies
An antibody is a protein produced by the body's immune system when it detects harmful substances, called antigens. Examples of antigens include microorganisms (such as bacteria, fungi, parasites, and viruses) and chemicals. Antibodies may be produc...